Note: This article was originally published on 9/13/2017 and has since been updated by NFCR Writers William Werkmeister and Brittany Ciupka. Blood cancers form in the bone marrow where blood is made or in the lymphatic system which protects us from infections. Background: More than 1.3 million people in the…...
Approved by the FDA in 1993, the drug cladribine offered hope for the then-fatal blood cancer called hairy cell leukemia, or HCL, and was soon expanded as a therapy for multiple sclerosis. Developed by NFCR scientist Dr. Dennis Carson at the University of California, San Diego, cladribine acts like a…...
When a loved one is diagnosed with cancer, friends and family want to do something to show their support and care for the patient. This often includes sending flowers, a card or cooking meals for the patient and their family. Unfortunately, many patients are immunosuppressant while going through cancer and…...
While it may not be an extremely common cancer, multiple myeloma, awareness of which is highlighted throughout the month of March, remains a severe life-threatening disease. Multiple myeloma is a cancer affecting plasma cells within the bone marrow. With the cancer impacting plasma cells, individuals living with multiple myeloma have…...
To bring attention to leukemia and lymphoma, Congress in 2010 designated September as Blood Cancer Awareness Month. These diseases are diagnosed in 14,000 people monthly within the United States. But with advances in treatment and technologies yielding earlier and earlier detection, the overall five-year relative survival rate for leukemia has…...
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) tax-exempt nonprofit organization.
Tax ID #: 04-2531031
